Biotech Values

[St_armands_man]

ENMD

Dew - I am currently holding some ENMD. I beleive that the price point is still attractive and management has been on target.

A poster on Yahoo today posted the following I believe he(she) is right on (tborges132)

One of the most encouraging comments to be made concerning the Burn's management team at EntreMed is their unfailing ability to establish and then achieve benchmarks. Burns-Sidor have been spot-on at achieving each of the stated goals of the past year. The commencement of Phase II studies at Duke is yet another benchmark.

While efficacy remains the big prize, we are now entering that part of the march to approval which will be all-telling.

Angioglioblastoma was one of the six indications targeted in Burn's letter of August 2005 in which he listed breast, prostate, ovarian, glioblastoma, multiple myeloma, and lung cancer as indications for multiple Panzem PII studies.

Based upon the indications noted, it is likely that the implementation of additional PII studies will follow.

The choice of Duke as the center for the current study appears to strengthen an alliance established with the previously announced Susan G. Komen grant for a Panzem study currently underway.

Do you want to know what will happen next? Pay attention to Burns... he has not missed a mark yet...